Figure 1.

Plasma FD levels. (A) FD levels were quantified in plasma samples from controls (n = 50), patients with Barraquer–Simons syndrome (BSS, n = 13), patients with C3 glomerulopathy (C3G, n = 22), and patients with acquired generalized lipodystrophy (AGL, n = 20). The results are presented as medians and interquartile ranges. Differences between groups were assessed by the Kruskall–Wallis test. p < 0.05 was considered statistically significant. (B) FD levels were assessed by Western blot, confirming that FD was elevated in patients with BSS and decreased in patients with AGL.